Abeona Therapeutics (ABEO)

[EdgeMCNJ]

As a result of growing interest surrounding the company's proprietary oral delivery technology, Access Pharmaceuticals, Inc. (OTCBB:ACCP) has submitted additional patent applications to cover oral formulations of many global top-100 injectable drugs. It is great to see such a growing interest in this proprietary oral delivery technology and not only will it aid sufferers of cancer, diabetes and many other illnesses but will help to create strong partnerships in the various pharmaceutical sectors. Access recently released its rinse for oral mucositis called MuGard in the U.S. and is receiving new prescriptions and reimbursements daily. The success full roll out of MuGard, the significant progress in bringing CobOral to market, as well as Access' roll with other innovative companies like iMedicor (VMCI) the national healthcare communications network, all continue to ensure that Access Pharmaceuticals will be a strong brand now and well into the future.

http://www.accesspharma.com/newsroom/access-pharmaceuticals-files-additional-ip-for-cobalamin-oral-delivery-technology/